NCT02649855 2024-08-06
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
13 trialsNCT01867333 2023-09-26
Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02326805 2023-07-19
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003871 2023-06-22
PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02649439 2022-11-14
Prostvac in Patients With Biochemically Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03532217 2022-08-05
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Washington University School of Medicine
Phase 1 Completed
NCT01875250 2020-09-16
Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01322490 2019-09-04
Prospect
Bavarian Nordic
Phase 3 Completed
NCT00060528 2017-10-26
Sequential Vaccinations in Prostate Cancer Patients
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00005916 2017-07-02
PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00020254 2015-04-29
Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00045227 2013-06-19
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00001382 2008-03-04
A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate
National Institutes of Health Clinical Center (CC)
Phase 1 Completed